Gabapentin and Cholecystitis acute - a phase IV clinical study of FDA data
Cholecystitis acute is found among people who take Gabapentin, especially for people who are female, 60+ old, have been taking the drug for < 1 month.
The phase IV clinical study analyzes which people take Gabapentin and have Cholecystitis acute. It is created by eHealthMe based on reports of 237,304 people who have side effects when taking Gabapentin from the FDA, and is updated regularly. You can use the study as a second opinion to make health care decisions.
With medical big data and AI algorithms, eHealthMe enables everyone to run phase IV clinical trial to detect adverse drug outcomes and monitor effectiveness. Our original studies have been referenced on 600+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Most recently, phase IV clinial trails for COVID 19 vaccines have been added, check here.
237,304 people reported to have side effects when taking Gabapentin.
Among them, 66 people (0.03%) have Cholecystitis acute.
What is Gabapentin?
Gabapentin has active ingredients of gabapentin. It is often used in neuralgia. eHealthMe is studying from 245,414 Gabapentin users for its effectiveness, alternative drugs and more.
What is Cholecystitis acute?
Cholecystitis acute (rapid infection of gallbladder) is found to be associated with 1,214 drugs and 770 conditions by eHealthMe.
Number of Gabapentin and Cholecystitis acute reports submitted per year:
Time on Gabapentin when people have Cholecystitis acute *:
- < 1 month: 33.33 %
- 1 - 6 months: 16.67 %
- 6 - 12 months: 0.0 %
- 1 - 2 years: 33.33 %
- 2 - 5 years: 16.67 %
- 5 - 10 years: 0.0 %
- 10+ years: 0.0 %
Gender of people who have Cholecystitis acute when taking Gabapentin *:
- female: 64.06 %
- male: 35.94 %
Age of people who have Cholecystitis acute when taking Gabapentin *:
- 0-1: 0.0 %
- 2-9: 0.0 %
- 10-19: 0.0 %
- 20-29: 11.67 %
- 30-39: 6.67 %
- 40-49: 10.0 %
- 50-59: 30.0 %
- 60+: 41.67 %
Common drugs people take besides Gabapentin *:
- Miralax: 13 people, 19.70%
- Neurontin: 12 people, 18.18%
- Tylenol: 11 people, 16.67%
- Zofran: 10 people, 15.15%
- Norco: 10 people, 15.15%
- Cymbalta: 9 people, 13.64%
- Lovenox: 9 people, 13.64%
- Omeprazole: 8 people, 12.12%
- Percocet: 8 people, 12.12%
- Yasmin: 8 people, 12.12%
Common side effects people have besides Cholecystitis acute *:
- Gallstones (stone formation by bile component): 14 people, 21.21%
- Stress And Anxiety: 7 people, 10.61%
- Abdominal Pain Upper: 6 people, 9.09%
- Chest Pain: 5 people, 7.58%
- Choledocholithiasis (stones in the common bile duct): 5 people, 7.58%
- Depressed Level Of Consciousness: 5 people, 7.58%
- Headache (pain in head): 5 people, 7.58%
- Diarrhea: 5 people, 7.58%
- Emotional Distress: 5 people, 7.58%
- Gallbladder Disorder: 4 people, 6.06%
Common conditions people have *:
- Neuropathy Peripheral (surface nerve damage): 12 people, 18.18%
- Constipation: 11 people, 16.67%
- Joint Pain: 10 people, 15.15%
- Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 10 people, 15.15%
- Depression: 10 people, 15.15%
- Back Pain: 9 people, 13.64%
- Hypothyroidism (abnormally low activity of the thyroid gland, resulting in retardation of growth and mental development): 8 people, 12.12%
- Stress And Anxiety: 8 people, 12.12%
- Arthritis (form of joint disorder that involves inflammation of one or more joints): 7 people, 10.61%
- High Blood Cholesterol: 7 people, 10.61%
* Approximation only. Some reports may have incomplete information.
Do you take Gabapentin and have Cholecystitis acute?Check whether Cholecystitis acute is associated with a drug or a condition
How to use the study?
You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.
Related publications that referenced our studies
- de Landaluce, L. O., Carbonell, P., Asensio, C., Escoda, N., López, P., & Laporte, J. R. , "Gabapentin and Pregabalin and Risk of Atrial Fibrillation in the Elderly: A Population-Based Cohort Study in an Electronic Prescription Database", Drug safety, 2018 Jan .
- Scarff JR, "The Potential for Somnambulism Associated with Gabapentin", The Internet Journal of Psychiatry, 2014 Jan .
Alternative drugs to, pros and cons of Gabapentin:
- Gabapentin (245,414 reports)
Cholecystitis acute treatments and more:
- Cholecystitis acute (6,480 reports)
COVID vaccines that are related to Cholecystitis acute:
- Cholecystitis acute in Moderna COVID Vaccine
- Cholecystitis acute in Pfizer BioNTech Covid Vaccine
- Cholecystitis acute in Johnson and Johnson Covid Vaccine
How severe was Cholecystitis acute and when was it recovered:
Expand to all the drugs that have ingredients of gabapentin:
Common drugs associated with Cholecystitis acute:
All the drugs that are associated with Cholecystitis acute:
- Cholecystitis acute (1,214 drugs)
Common conditions associated with Cholecystitis acute:
All the conditions that are associated with Cholecystitis acute:
- Cholecystitis acute (770 conditions)
How the study uses the data?
The study uses data from the FDA. It is based on gabapentin (the active ingredients of Gabapentin) and Gabapentin (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.
Who is eHealthMe?
With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).
WARNING, DISCLAIMER, USE FOR PUBLICATION
WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.
DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.
If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.